Galectin Therapeutics Inc., formerly Pro-Pharmaceuticals, Inc., is a development-stage company engaged in the discovery and development of Galectin-targeting therapeutics. The Company focuses on the development of anti-cancer treatments using polysaccharide polymers. As of December 31, 2009, the Company's products were in development, including pre-clinical and clinical trials. As of December 31, 2009, the Company was developing a pipeline of compounds that may be combined with chemotherapies, such as 5-FU and biologics, such as Avastin. As of December 31, 2009, DAVANAT had been administered to approximately 100 cancer patients in Phase I and II trials. As of December 31, 2009, the Company was developing other therapeutic compounds for treatment of other serious disease, such as liver and kidney fibrosis. These product candidates are all in the pre-clinical stage of development...
post #1 of 4
4/12/12 at 11:36pm